Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis

Παρόμοια τεκμήρια

• Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor α
  ανά: Van den Bosch, F, κ.ά.
  Έκδοση: (2001)
• Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy
  ανά: Kruithof, E, κ.ά.
  Έκδοση: (2005)
• Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up
  ανά: Kruithof, E, κ.ά.
  Έκδοση: (2002)
• Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study
  ανά: Van den Bosch, F., κ.ά.
  Έκδοση: (2000)
• Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?
  ανά: Baeten, D, κ.ά.
  Έκδοση: (2003)